Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently ...

6 With regard to the gold-standard GFR method used by Schwartz and colleagues ... to identify the onset of renal insufficiency and end-stage renal disease and to errors in the prescribed dosage ...

a significantly lower decline in GFR was found during remission, thus predicting a better outcome in terms of survival and survival free of end-stage renal failure. To improve the treatment and ...

They excluded patients with chronic kidney disease (CKD) stage 3 or higher. The early loss of renal function was defined as a loss in glomerular filtration rate (GFR) >3.3% per year. Of 355 ...

Chronic Kidney Disease (CKD) indicates prolonged kidney damage over three months, often undetectable until significant harm occurs. Key risk factors include diabetes, high blood pressure, and obesity.

In February, the Clinical Kidney Journal published MediBeacon data in an article on Chronic Kidney Disease (CKD) stage misclassification via estimated GFR (eGFR) compared to measured GFR (mGFR ...

using relmapirazin versus estimated GFR (eGFR) for the purpose of classifying patient Chronic Kidney Disease (CKD) stages. MediBeacon TGFR study results have been posted online in the February ahead ...